GoodRx launched GoodRx Employer Direct, a program that allows employers to subsidize manufacturer-sponsored prices for high-cost brand medications like GLP-1s without adding them to their health insurance benefits. The post GoodRx Launches Employer Program to Help Subsidize High-Cost Brand Drugs appeared first on MedCity News.
Senators John Kennedy (R-Louisiana) and Eric Schmitt (R-Missouri) introduced a bill last week that would require “able-bodied adults” without dependents to work or volunteer for at least 20 hours per week to receive Medicaid benefits. The post Senators Introduce Bill that would Add Work Requirements for Medicaid appeared first on MedCity News.
Innovative solutions like biometric authentication and adaptive identity management are paving the way for more secure, efficient, and user-friendly mobile device use
This brief features maps showing how insurer participation has changed at the state and county level from 2025 to 2026 as well as insight into the number of issuers offering plans at specific metal levels.
Surescripts and GoodRx launched Script Corner, a tool that gives patients upfront visibility into prescription prices and savings options. The post Surescripts Launches Prescription Price Transparency Tool With GoodRx appeared first on MedCity News.
Health tech companies made several major funding announcements in April. Here is a list of some of the biggest funding rounds. The post 4 Notable Health Tech Funding Announcements in April appeared first on MedCity News.
The House Committee on Appropriations approved the FY 2026 National Security, Department of State, and Related Programs (NSRP) appropriations bill and accompanying report on July 23, 2025. The NSRP bill includes funding for U.S. global health programs at the State Department through the Global Health Programs (GHP) account, which represents the bulk of global health…More
By MIKE MAGEE “The technological leaps of the 1900s — microelectronics, antibiotics, chemotherapy, liquid-fueled rockets, Earth-observing satellites, lasers, LED lights, disease-resistant seeds and so forth — derived from science. But these technologies also spent years being improved, tweaked, recombined and modified to make them achieve the scale and impact necessary for innovations.” Jon Gertner, author of “The Idea…
[Sponsored] FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease. The post Understanding EGPA: The Role of Eosinophils and Advancements in Treatment Options appeared first on MedCity News.
Novo Nordisk, AbbVie, and Roche each have weekly injectable drug candidates designed to bind to and activate the amylin receptor to trigger weight loss. Metsera’s contender, MET-233i, is designed with technology that enables longer dosing intervals and the company is proceeding with development of this engineered peptide as a monotherapy and as part of a…